The surge in passive institutional ownership, particularly the massive stake expansion by Morgan Stanley, may signal confidence in BioA's valuation or upcoming catalysts. Traders should monitor for follow-on buying, increased liquidity, and potential inclusion in broader index flows. Given the small absolute dollar size relative to market cap ($930M), this is a directional signal rather than a fundamental transformation.
BIOA drugs
BIOA drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 2 $21.71entry
- T+1 · 9mo ago −5.76%α −4.84% · $20.46
- T+5 · 8mo ago −9.12%α −7.91% · $19.73
- T+20 · 8mo ago −27.08%α −19.15% · $15.83
- T+60 · 6mo ago −25.38%α −34.71% · $16.20
How similar events traded
Executive Summary
Three major passive institutions, Morgan Stanley, Wells Fargo, and Schwab, significantly increased their positions in BioAge Labs (BIOA) during Q4 2024, collectively adding $3.0M in new holdings. Morgan Stanley doubled its stake with a massive share increase, while Wells Fargo and Schwab initiated new positions. This coordinated accumulation by large financial intermediaries suggests growing institutional interest in the stock.
Key Financial Metrics
Institutional Positions
Net institutional flow: $3.1M
▲ Buyers (3)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Morgan Stanley | DOUBLED | +19083.8% | $2.6M | $2.6M |
| Wells Fargo | NEW | +0% | $36.0K | $36.0K |
| Schwab | NEW | +0% | $491.0K | $491.0K |
Key Facts
- Morgan Stanley doubled its stake in BIOA, increasing shares from 2.3K to 443.0K (a 19083.8% rise), adding $2.5M in value.
- Wells Fargo initiated a new position with 6.3K shares worth $36K.
- Schwab initiated a new position with 84.9K shares worth $491K.
- No institutional selling was detected in this quarter, all tracked activity was net buying.
Financial Impact
3 institutions accumulated $3.0M in new positions during Q4 2024, with total current holdings now at $3.1M.
Risk Factors
- All buyers are mega-passive institutions, suggesting the moves may reflect index rebalancing or mechanical flows rather than active conviction.
- The total institutional investment remains small ($3.1M) relative to the company's $930M market cap, limiting immediate price impact.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-BIOA-2024-Q4 |
Track record
11 reports on BIOA
2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +13.00% at T+60 after the Apr 21, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $5.50 settles Nov 23
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $5.34 to $5.55 ▲ +3.93% +1.34% vs SPY
- Jun 16, 202621w ago Press Release Neutral 3/10 Entry $20.49 to $22.32 ▲ +8.93% +11.16% vs SPY
- May 8, 202627w ago 8-K Bullish 7/10 Entry $17.99 to $18.72 ▲ +4.03% +2.57% vs SPY
- Apr 21, 202629w ago DEFA14A Neutral 3/10 Entry $18.36 to $17.14 ▼ −6.64% −6.70% vs SPY
- Apr 21, 202629w ago Press Release Bullish 8/10 Entry $19.61 to $17.44 ▼ −11.07% −12.15% vs SPY
- Apr 1, 202632w ago 144 Neutral 3/10 Entry $17.73 to $17.79 ▲ +0.34% −3.43% vs SPY
- Mar 24, 202633w ago Press Release Mixed 6/10 Entry $16.11 to $17.49 ▲ +8.57% +8.99% vs SPY
- Mar 2, 202637w ago Court Ruling Bullish 7/10 Entry $20.46 to $20.97 ▲ +2.49% +2.96% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers